REPRINT: Good laboratory practice: Preventing introduction of bias at the bench

Malcolm R. Macleod, Marc Fisher, Victoria O'collins, Emily S. Sena, Ulrich Dirnagl, Philip M.W. Bath, Alistair Buchan, H. Bart Van Der Worp, Richard J. Traystman, Kazuo Minematsu, Geoffrey A. Donnan, David W. Howells*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

As a research community, we have failed to demonstrate that drugs that show substantial efficacy in animal models of cerebral ischemia can also improve outcome in human stroke. Accumulating evidence suggests that this may be due, at least in part, to problems in the design, conduct and reporting of animal experiments, which create a systematic bias resulting in the overstatement of neuroprotective efficacy. Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.

Original languageEnglish
Pages (from-to)3-5
Number of pages3
JournalInternational Journal of Stroke
Volume4
Issue number1
DOIs
Publication statusPublished - 25 Feb 2009

Keywords

  • Animal experiments
  • Animal models
  • Cerebral ischemia
  • Good practice
  • Neuroprotective efficacy
  • Reporting

Fingerprint

Dive into the research topics of 'REPRINT: Good laboratory practice: Preventing introduction of bias at the bench'. Together they form a unique fingerprint.

Cite this